medicines

RCEP: Robbing communities to extract profit

14-Oct-2017 APWLD

RCEP will give multinational corporations unprecedented rights

Free trade talks with EFTA grouping hit IPR, services wall

26-Sep-2017 The Hindu

Switzerland insists on intellectual property commitments beyond TRIPS.

Sanofi Aventis Ukraine seeks to file claim to international court to protect investment in Ukraine

18-Sep-2017 Interfax

Sanofi Aventis Ukraine LLC, part of Sanofi global pharmaceutical company, seeks to file a claim against Ukraine to the International Investment Arbitration.

Foreign patent owners can challenge domestic judgments under international investment arbitration

12-Sep-2017 Forbes India

The first ever final award on patents in international investment arbitration by ICSID in the case of Eli Lilly v. Canada has effectively cleared the way for raising future disputes by foreign IPR owners against domestic institutions which can result in stronger and robust IP protection regime.

Canada introduces patent term extensions for pharmaceutical patents

12-Sep-2017 Lexology

The new regime has been implemented in order to meet Canada’s obligations under the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union

TPP 11 Sydney meeting vindicates community concerns

1-Sep-2017 AFTINET

TPP 11 negotiators have agreed to suspend controversial clauses on medicine monopolies and some governments want to renegotiate other clauses, vindicating public interest group concerns

Vietnam proposes amendments to stalled TPP trade deal at Sydney talks: sources

29-Aug-2017 Reuters

Officials from 11 of the 12 countries that committed to the Trans-Pacific Partnership (TPP) trade deal are meeting in Sydney for talks to re-energize the stalled agreement and discuss amendmends to the pact following the withdrawal of the US.

Health community’s concerns re TPP11 proposed next steps

24-Aug-2017

Stronger intellectual property protection would benefit the US in return for no concessions, civil society groups tell TPP11 Ministers

Pharmaceutical prices, intellectual property rights emerge as key issues in KORUS FTA discussions

24-Aug-2017 Hankyoreh

Through the KORUS revision, the US is openly seeking to bridge its trade deficit with Korea by renegotiating specific terms for individual product categories.

Neelam Deo on EU-India’s perplexing relationship: Trade, Europe’s hypocrisy and China concern

23-Aug-2017 EU Bulletin

Former diplomat says the EU’s insistence on opening up on wine imports from France and automobile imports from Germany have held up the EU-India FTA negotiations.

Big pharma, IP wars and profit over people

21-Aug-2017 Governance Now

At RCEP negotiations held in India, intellectual property rights issues in medicine remain contentious

NAFTA could replay TPP biologics debate

19-Aug-2017 Politico

A battle over the length of data protection for biologic medicine appears to be shaping up in the NAFTA negotiations in a replay of an issue that helped block the Trans-Pacific Partnership from becoming law.

Interview with Loon Gangte

4-Aug-2017 bilaterals.org

Loon Gangte is an Indian activist living with HIV and hepatitis C, founder of the Delhi Network of Positive People.

Medicines in India likely to be costlier due to RCEP trade pact

2-Aug-2017 DNA

However, the key issues holding the final text of these negotiations don’t seem to be getting resolved.

New Zealand negotiator at Asia trade pact talks says countries should analyse TRIPS-Plus

1-Aug-2017 The Wire

The negotiator’s comments were non-committal but indicated that for now, the RCEP talks have not yet moved decisively into a TRIPS-plus scenario.

ASEAN Parliamentarians call for a focus on rights in regional trade talks

24-Jul-2017 Asian Tribune

Officials from ASEAN member states and other countries meeting in India this week for negotiations on the Regional Comprehensive Economic Partnership (RCEP) should take steps to ensure that the trade deal safeguards human rights, Southeast Asian lawmakers said today.

Trading health through IPR, patents

17-Jul-2017 Deccan Herald

Trade agreements between countries have a perceivable impact on access to medicines as a result of changes in patent and other national laws in different countries.

Canada blinks in face of US/Pharma pressure

14-Jul-2017 Info Justice

The cool reasoning of the Canadian Supreme Court does not acknowledge or reference “external” pressures or the Eli Lilly v. Canada ISDS case. However, courts do not decide cases in a vacuum. This case seems to have been decided in a pressure cooker.